INBX
Inhibrx Biosciences Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +2.7% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 69 | +7 | 7.66M | $725.26M | +12 | −5 |
| Q1 2026 | 65 | -3 | 7.61M | $511.38M | +3 | −7 |
| Q4 2025 | 69 | 0 | 8.07M | $637.42M | +2 | −1 |
| Q3 2025 | 17 | +7 | 4.45M | $150.05M | +7 | n/a |
| Q2 2025 | 7 | 0 | 3.86M | $55.09M | n/a | n/a |
| Q1 2025 | 4 | -1 | 2.48M | $34.64M | n/a | −1 |
| Q4 2024 | 5 | -2 | 2.53M | $38.98M | n/a | −2 |
| Q3 2024 | 6 | +1 | 2.46M | $38.48M | +2 | −1 |
| Q2 2024 | 5 | n/a | 2.53M | $35.86M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 1.79M | 0.0% | $60.21M | 0.2% | Held | 6 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 684.75K | -6.0% | $23.06M | 0.0% | ▼ Trim | 2 | SEC ↗ ×8 |
| 3 | The Vanguard Group ✦ (passive) | 594.92K | -0.6% | $20.04M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 4 | Morgan Stanley ✦ | 442.86K | n/a | $14.92M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 5 | Millennium Management ✦ | 297.82K | +8.0% | $10.03M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 221.92K | -1.8% | $7.48M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (passive) | 203.92K | -0.5% | $6.87M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 57.19K | New | $1.93M | 0.0% | New | 1 | SEC ↗ ×2 |
| 9 | Fidelity (FMR) ✦ | 39.33K | +0.7% | $1.32M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 10 | Wellington Management ✦ | 29.76K | New | $1.00M | 0.0% | New | 1 | SEC ↗ ×3 |
| 11 | Marshall Wace ✦ | 27.24K | New | $917,511 | 0.0% | New | 1 | SEC ↗ |
| 12 | Goldman Sachs Group ✦ | 25.97K | n/a | $874,535 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 11.55K | New | $389,105 | 0.0% | New | 1 | SEC ↗ |
| 14 | JPMorgan Chase ✦ | 9.66K | n/a | $325,282 | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 15 | Renaissance Technologies ✦ | 8.40K | New | $282,912 | 0.0% | New | 1 | SEC ↗ |
| 16 | Arrowstreet Capital ✦ | 6.00K | New | $202,181 | 0.0% | New | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 6.00K | New | $202,013 | 0.0% | New | 1 | SEC ↗ ×5 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $1.93M | 0.0% |
| Wellington Management | $1.00M | 0.0% |
| Marshall Wace | $917,511 | 0.0% |
| D. E. Shaw & Co. | $389,105 | 0.0% |
| Renaissance Technologies | $282,912 | 0.0% |
| Arrowstreet Capital | $202,181 | 0.0% |
| AQR Capital Management | $202,013 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 134 holders, 12.71M shares, $853.40M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · Chief Executive… · 2.47K sh @ 84.07 · $207,655
Officer, Director · Chief Executive… · 100 sh @ 85.76 · $8,576
Officer, Director · Chief Executive… · 2.45K sh @ 85.00 · $208,333
Officer, Director · Chief Executive… · 2.45K sh @ 84.07 · $205,889
Officer, Director · Chief Executive… · 100 sh @ 85.76 · $8,576
Officer, Director · Chief Executive… · 2.47K sh @ 85.00 · $209,948
Officer, Director · Chief Executive… · 3.00K sh @ 101.70 · $305,106
Officer, Director · Chief Executive… · 1.50K sh @ 98.88 · $148,320
Officer, Director · Chief Executive… · 2.18K sh @ 99.60 · $216,727
Officer, Director · Chief Executive… · 3.32K sh @ 98.87 · $328,630
Open-market sales (S)
Director · 500 sh · $52,525
Director · 500 sh · $55,130
Director · 500 sh · $55,888
Director · 500 sh · $57,898
Director · 500 sh · $57,570
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology